drklehrinstitut
pi
de
us
uk
hr
si
bg
ru
   Home
 Information for Patients
 Information for Oncologists
 About Us
 Contact Us
 Links
TUMORSPECIFIC IMMUNO-THERAPY
 
This treatment is developed by our institute and patented by Deutsches Patentamt (registrated:DE 3923848 C2).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROCEDURE:
 
In 1st step after drawing peripheral blood we separate the surface of tumor-cells and tumorantigen-loaded makrophages.
In 2nd step we remove about 60 to 80 % of their outer cellmembran ().
In 3rd step we present to immunological active cells of peripheral blood in vitro these removed parts of cellmembran and in addition the "nude" cancer-cells ().With this procedure immun-active cells express in the laboratory antibodies and cytokines towards this removed camouflage on the one hand, and on the other hand to nude tumor-cells ().
In 4th step we harvest these tumor-specific antibodies and cytokines (towards nude cancer-cells and their mimigree) and use it for treatment.
 
 
COMMENT:
 
Immun-active cells in vivo cannot express antibodies and cytokines towards cancer-cells, since protection by mimigree in vivo is done.In vitro antibodies and cytokines can be expressed, since by laboratory-procedure mimigree is removed. So in vitro immun-activ cells express (what in vivo is blocked by mimigree) antibodies and cytokines specific towards the tumor-cells.
Bringing back these patients own tumorspecific antibodies and cytocines (signal-transducers) in patients system, white blood cells in vivo "read" this message and find all the immunologically hidden tumor-cells in patients organism. Since antibodies and in special cytokines are signal-transducers, comparison is allowed with a wanted paper, that is expressed in vitro and given back therapeutically in vivo to support patient's immun-active cells.
 
 
CLINICAL ASPECTS:
 
Under this treatment clinically appears natural immunological defence anywhere tumor oder metastases are located in form of inflammation. This inflammation is the beginning of the therapeutic effect and is followed by tumor-decrease. Naturally these reactions are depending on tumor- or metastases-size, -location, and dependant on the activity of patient´s immun-system.
Very important is, that this expression of cytokines is controlled. So first of all documentation is done of
 
    Tumornecrosefactor a,
   Interleukin 2- and
   Interleukin 6-receptor
 
from the native serum. Under the described laboratory procedure cytokines will be expressed more or less. If laboratory procedure is stopped, second examination of the upon mentioned cytokines is done. So beginning on 200 % or more of the basic serum-cytokines are expressed, the therapy will be started. Otherwise, if less than 200 % of cytokines are expressed, no specific antitumor-effect will be expected, no therapy will be done. The laboratory-procedure has to be repeated.
So this technique also allows to predict any therapeutic effect, what is just in onkology very importantThis technique also is suitable for Early Cancer Detection.
 
 
P.S.: Our laboratory is accredited by College of American Pathologists.
Literature: Please see  Literatur :(1-5) = [23-27] (Literatur)(6) = [33] (Literatur)(7) = [27] (Literatur)Please mention : This is a part of a handbook for medical practiceOwn Blood - Therapy and other Autologous TherapiesHaug publishing house 2000
dia
BASICS:
 
The basis of the laboratory procedure is the knowledge, that also every healthy person produces thousands of cancer-cells every day. These cells are detected by immuno-system immediately and repaired or destroied.Cancer-development includes, that primary a clone of tumor-cells grows up, that prevents from immunological detection by camouflage resp. mimigree. Since scientific knowledge of today comes to conclusion, that tumor-cells express surface-markers, that are identically to normal (organ- oder tissue-)cells, it is accepted, that this way of mimigree prevents immunological detection.Also well known is, that even in early stage of cancer tumor-cells already circulate in peripheral blood (Lit. 1, 2, 3, 4, 5, ), preventing from detection by expressing f.e. CD44v (Lit. 6) in the same way, as lymphocytes do, and keep so far from detection (Lit. 7).